HC Wainwright Reaffirms “Buy” Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)

Mirum Pharmaceuticals (NASDAQ:MIRM)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $130.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 47.93% from the company’s current price.

Several other brokerages also recently commented on MIRM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Raymond James Financial reissued a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Leerink Partners lowered their price objective on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Wall Street Zen lowered Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Robert W. Baird upped their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $117.00.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $87.88 on Monday. The company has a fifty day moving average price of $96.49 and a 200-day moving average price of $81.53. The company has a market capitalization of $5.30 billion, a P/E ratio of -183.08 and a beta of 0.52. Mirum Pharmaceuticals has a 52-week low of $36.88 and a 52-week high of $109.28. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.13). The business had revenue of $148.93 million during the quarter, compared to the consensus estimate of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The business’s revenue for the quarter was up 49.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.00 EPS. As a group, equities analysts expect that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,985 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the completion of the sale, the chief executive officer directly owned 194,309 shares in the company, valued at approximately $17,872,541.82. This trade represents a 17.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jolanda Howe sold 4,732 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $435,249.36. Following the completion of the transaction, the senior vice president directly owned 8,429 shares of the company’s stock, valued at approximately $775,299.42. This trade represents a 35.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 121,942 shares of company stock valued at $11,416,645. 22.87% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in MIRM. Cullen Frost Bankers Inc. bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $30,000. MCF Advisors LLC increased its stake in shares of Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $32,000. CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $32,000. Finally, Quantbot Technologies LP acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $33,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.